乙炔基酪胺 | 115062-49-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 乙炔基酪胺
• 英文名称: 4-(1-Aminomethyl-prop-2-ynyl)-phenol
• 英文别名: 4-(1-(Aminomethyl)-2-propynyl)phenol；4-(1-aminobut-3-yn-2-yl)phenol
• CAS: 115062-49-2
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: RSTGIJNRFQUESV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  {2-[4-(4-Methoxy-benzyloxy)-phenyl]-but-3-ynyl}-carbamic acid 4-methoxy-benzyl ester 在 盐酸 作用下， 以 乙醚 、 乙酸乙酯 为溶剂， 生成 乙炔基酪胺
  参考文献：
  名称：

  β-取代的苯乙胺是多巴胺β-羟化酶的基于高亲和力机理的抑制剂。

  摘要：

  DOI：

  10.1021/jm00399a002

文献信息

• Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
  申请人：G.D. Searle & Co.

  公开号：US20030220521A1

  公开（公告）日：2003-11-27

  Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-&bgr;-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-&bgr;-hydroxylase inhibitors, of which N-acetyl-&ggr;-glutamyl fusaric acid hydrazide (shown below) is preferred. 1

  本文描述了一种肾选择性的前药，其在肾脏中优先转化为能够抑制参与肾交感神经活动的儿茶酚型神经递质合成的化合物。本文所描述的前药来源于能够抑制儿茶酚合成中的一个或多个酶的抑制剂化合物，这些化合物可分类为酪氨酸羟化酶抑制剂，多巴脱羧酶抑制剂或多巴胺-&bgr;-羟化酶抑制剂。这些抑制剂化合物通过可被肾脏中大量存在的酶选择性识别的可裂解键与化学基团（如谷氨酸衍生物）连接。释放的抑制剂化合物然后可在肾脏中用于抑制儿茶酚合成中的一个或多个酶。抑制肾脏儿茶酚合成可抑制与钠潴留相关的疾病（如高血压）相关的增强肾脏神经活动。特别感兴趣的共轭物是多巴胺-&bgr;-羟化酶抑制剂的谷氨酰衍生物，其中N-乙酰-&ggr;-谷氨酰富萨酸肼（如下图所示）是首选。1
• Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
  申请人：G.D. Searle & Co.

  公开号：US20040101523A1

  公开（公告）日：2004-05-27

  Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-&bgr;-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-&bgr;-hydroxylase inhibitors, of which N-acetyl-&ggr;-glutamyl fusaric acid hydrazide (shown below) is preferred. 1

  本文描述了肾脏选择性前药，这些前药被优先转化为能够抑制与肾脏交感神经活动相关的儿茶酚类神经递质合成的化合物。所述前药源自能够抑制儿茶酚类合成中涉及的一个或多个酶的抑制剂化合物，这些化合物可分类为酪氨酸羟化酶抑制剂，或多巴脱羧酶抑制剂，或是多巴胺-β-羟化酶抑制剂。这些抑制剂化合物与化学基团（例如谷氨酸衍生物）通过可被肾脏内的酶特异性识别的可切断键连接。被释放的抑制剂化合物随后可在肾脏中抑制一个或多个涉及儿茶酚类合成的酶。抑制肾脏儿茶酚类合成可以抑制与钠潴留相关的疾病（如高血压）所伴随的过度肾脏神经活动。特别感兴趣的结合物是多巴胺-β-羟化酶抑制剂的谷氨酰衍生物，其中N-乙酰-γ-谷氨酰菌核酸酸肼（如下图所示）是首选。1
• Irreversible dopamine-Beta-hydroxylase inhibitors
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0250264A1

  公开（公告）日：1987-12-23

  Substituted β-ethenyl and β-ethynyl benzeneethanamine compounds of structrue (I) in which X is hydrogen or hydroxy; and R is ethenyl or ethynyl; are potent, irreversible inhibitors of mammalian dopamine-β-hydroxylase. Included are pharmaceutical compositions and methods for using these compounds to inhibit DH, and processes and intermediates used in preparing active compounds.

  结构式为(I)的取代 β-乙烯基和 β-乙炔基苯乙胺化合物 其中 X 为氢或羟基；R 为乙烯基或乙炔基；是哺乳动物多巴胺-β-羟化酶的强效不可逆抑制剂。包括使用这些化合物抑制 DH 的药物组合物和方法，以及用于制备活性化合物的工艺和中间体。
• Modular approach to on-line synthesis, drug discovery and biochemical transformations using immobilized enzyme reactors
  申请人：——

  公开号：US20040053355A1

  公开（公告）日：2004-03-18

  A coupled system using extremely different enzymes with incompatible cofactors and reaction conditions has been constructed using standard liquid chromatographic formats and open tubular formats. One of the significant aspects of the present invention lies in the development of the liquid chromatographic on-line enzyme cascade. This has been illustrated by the biosynthetic pathway involving dopamine beta-hydroxylase and phenylethanolamine N-methyltransferase which encompass the synthesis of the key neurotransmitters, norepinephrine and epinephrine. The results demonstrate for the first time the immobilization of dopamine beta-hydroxylase and phenylethanolamine N-methyltransferase. The IMERs are active and can be used in a liquid chromatographic format for qualitative and quantitative determinations. The IMER-HPLC system can be used to carry out standard Michaelis-Menten enzyme kinetic studies and to quantitatively determine enzyme kinetic constants, identify specific enzyme inhibitors, provide information regarding the mode of inhibition and the inhibitor constants (K i ). A second significant aspect of the present invention lies in the ability of the immobilized enzyme reactors to be used independently or as a combination, thus providing a unique opportunity to explore the interrelationships between these enzymes, to investigate the source of diseases and to design new drug entities for identified clinical syndromes.

  利用标准液相色谱格式和开放式管式格式，构建了一个使用极其不同的酶与不相容的辅助因子和反应条件的耦合系统。本发明的一个重要方面在于开发了液相色谱在线酶级联。多巴胺 beta-羟化酶和苯乙醇胺 N-甲基转移酶参与的生物合成途径说明了这一点，这两种酶包括合成关键的神经递质--去甲肾上腺素和肾上腺素。研究结果首次证明了多巴胺 beta-羟化酶和苯乙醇胺 N-甲基转移酶的固定化。IMER 具有活性，可用于液相色谱法进行定性和定量测定。IMER-HPLC 系统可用于开展标准的 Michaelis-Menten 酶动力学研究，定量测定酶动力学常数，确定特定的酶抑制剂，提供有关抑制模式和抑制剂常数（K i ).本发明的第二个重要方面在于固定化酶反应器能够独立使用或组合使用，从而为探索这些酶之间的相互关系、研究疾病的来源以及为已确定的临床综合症设计新的药物实体提供了独特的机会。
• .beta.-Substituted phenethylamines as high-affinity mechanism-based inhibitors of dopamine .beta.-hydroxylase
  作者：Lawrence I. Kruse、Carl Kaiser、Walter E. DeWolf、Pamela A. Chambers、Paula J. Goodhart、Mildred Ezekiel、Eliot H. Ohlstein

  DOI：10.1021/jm00399a002

  日期：1988.4